HomeComparePGNN vs ABBV

PGNN vs ABBV: Dividend Comparison 2026

PGNN yields 16.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $45.4K in total portfolio value· pulled ahead in Year 7
10 years
PGNN
PGNN
● Live price
16.00%
Share price
$12.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.0K
Annual income
$4,284.03
Full PGNN calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PGNN vs ABBV

📍 ABBV pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPGNNABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PGNN + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PGNN pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PGNN
Annual income on $10K today (after 15% tax)
$1,360.00/yr
After 10yr DRIP, annual income (after tax)
$3,641.43/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $17,414.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PGNN + ABBV for your $10,000?

PGNN: 50%ABBV: 50%
100% ABBV50/50100% PGNN
Portfolio after 10yr
$79.6K
Annual income
$14,527.89/yr
Blended yield
18.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PGNN
No analyst data
Altman Z
-0.9
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PGNN buys
0
ABBV buys
0
No recent congressional trades found for PGNN or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPGNNABBV
Forward yield16.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$57.0K$102.3K
Annual income after 10y$4,284.03$24,771.77
Total dividends collected$28.6K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PGNN vs ABBV ($10,000, DRIP)

YearPGNN PortfolioPGNN Income/yrABBV PortfolioABBV Income/yrGap
1$12,300$1,600.00$11,550$430.00+$750.00PGNN
2$15,000$1,839.25$13,472$627.96+$1.5KPGNN
3$18,147$2,096.29$15,906$926.08+$2.2KPGNN
4$21,787$2,370.08$19,071$1,382.55+$2.7KPGNN
5$25,971$2,659.38$23,302$2,095.81+$2.7KPGNN
6$30,752$2,962.76$29,150$3,237.93+$1.6KPGNN
7← crossover$36,183$3,278.63$37,536$5,121.41$1.4KABBV
8$42,322$3,605.31$50,079$8,338.38$7.8KABBV
9$49,225$3,941.04$69,753$14,065.80$20.5KABBV
10$56,955$4,284.03$102,337$24,771.77$45.4KABBV

PGNN vs ABBV: Complete Analysis 2026

PGNNStock

Paragon Financial Solutions, Inc., through its subsidiary, Paragon Bank, provides various banking products and services to individuals, and small and mid-sized businesses in the United States. It offers deposit products, including checking accounts, savings accounts, money market savings accounts, certificates of deposit, and IRAs. The company also provides commercial loan products comprising working capital loans, accounts receivable/inventory lines of credit, equipment financing, commercial auto/truck financing, business acquisition financing, letters of credit, SBA/USDA lending, and owner-and non-owner-occupied commercial real estate loans; and mortgage loans, such as purchase, refinance, conventional mortgage, federal housing administration, veterans affairs, affordable home, home equity, and medical specialist loans. In addition, it offers private banking services, such as depository and personal financial services, as well as special purchases, residential mortgages, home equity, construction and renovation, and vacation and second homes loan and credit services; cash management solutions consisting of liquidity, fraud prevention, and payables and receivables management; and wealth solutions, including equities, mutual funds, bonds, and annuity products and services. Further, the company provides insurance solutions, such as property, general liability, group medical plans, long and short-term disability, professional liability, workers compensation, truckers/cargo, auto, home, umbrella, aviation, and surety bonds, as well as employee dental, vision, and life insurance. It also offers mobile, online, phone, and internet banking services. The company operates approximately 150 ATM locations in the Memphis metro area. Paragon Financial Solutions, Inc. was founded in 2004 and is based in Memphis, Tennessee.

Full PGNN Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PGNN vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PGNN vs SCHDPGNN vs JEPIPGNN vs OPGNN vs KOPGNN vs MAINPGNN vs JNJPGNN vs MRKPGNN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.